Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of iPS-NKT cell plus autologous DC/Gal for recurrent or advanced head and neck cancer
jRCTa030220741Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2024
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iPS-NKT cell and autologous dendritic cell/Gal in head and neck cancer (HNC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of dose-limiting toxicity. Started Feb 2024; status: recruiting.
02
Drugs
iPS-NKT cellautologous dendritic cell/Gal
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCTa030220741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa030220741.